• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Y-mAbs Therapeutics Inc.

    3/4/25 7:48:33 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $YMAB alert in real time by email
    S-8 1 tmb-20250304xs8.htm S-8

    As filed with the Securities and Exchange Commission on March 4, 2025

    Registration No. 333-

    ​

    ​

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    Y-mAbs Therapeutics, Inc.

    (Exact name of Registrant as specified in its charter)

    ​

    Delaware

    47-4619612

    (State or other jurisdiction of incorporation or organization)

    (I.R.S. Employer Identification No.)

    ​

    202 Carnegie Center Suite 301

    Princeton, NJ 08540

    (Address of principal executive offices) (Zip code)

    2018 Equity Incentive Plan

    (Full title of the plans)

    Michael Rossi

    President and Chief Executive Officer

    Y-mAbs Therapeutics, Inc.

    202 Carnegie Center Suite 301

    Princeton, New Jersey 08540

    Tel: (646) 885-8505

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Divakar Gupta

    Sarah K. Sellers

    Cooley LLP

    55 Hudson Yards

    New York, NY 10001

    Telephone: (212) 479-6000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    ​

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

    ​

    ​

    ​


    ​

    EXPLANATORY NOTE

    Y-mAbs Therapeutics, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) for the purpose of registering 1,799,532 shares of the Registrant’s common stock, par value $0.0001 per share (the “Common Stock”), issuable to eligible persons under the Registrant’s 2018 Equity Incentive Plan (the “2018 EIP”), which Common Stock is in addition to, and of the same class as, the shares of Common Stock for which the Registrant previously filed registration statements on Form S-8 (File Nos. 333-230455,  333-271007, and 333-277541) with the Commission on March 22, 2019, March 30, 2023 and February 29, 2024, respectively (the “Prior S-8 Registration Statements”). Accordingly, the contents of the Prior S-8 Registration Statements are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8. The additional shares of Common Stock registered hereby have become reserved for issuance as a result of the operation of the “evergreen” provision in the 2018 EIP, which provides that the total number of shares subject to the plan may be increased each year pursuant to a specified formula as set forth in the 2018 EIP.

    PART II

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 4, 2025.

    The Registrant’s Current Report on Form 8-K filed with Commission on January 10, 2025.

    The description of the Registrant’s Common Stock which is contained in Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Commission on March 4, 2025.

    The contents of the Registrant’s Registration Statements on Form S-8 filed with the Commission on March 22, 2019 (File No. 333-230455), March 30, 2023 (File No. 333-271007) and February 29, 2024 (File No. 333-277541), pursuant to which the Registrant previously registered shares of its Common Stock for issuance under the 2018 EIP.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    1

    ​


    ITEM 8. EXHIBITS

    Incorporated by Reference

    Exhibit
    Number

    Description

    Schedule
    Form

    File Number

    Exhibit

    Filing Date

    4.1

    Amended and Restated Certificate of Incorporation.

    8-K

    001-38650

    3.1

    September 26, 2018

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    4.2

    Amended and Restated Bylaws.

    8-K

    001-38650

    3.2

    September 26, 2018

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    4.3

    Specimen stock certificate evidencing the shares of Common Stock.

    S-1

    333-226999

    4.1

    September 7, 2018

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    99.1

    2018 Equity Incentive Plan

    S-1

    333-226999

    10.9

    August 24, 2018

    ​

    ​

    ​

    ​

    ​

    ​

    99.2

    Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan.

    10-Q

    001-38650

    10.1

    November 7, 2020

    ​

    ​

    ​

    ​

    ​

    ​

    99.3

    Form of Stock Option Grant Notice and Stock Option Agreement for directors under the 2018 Equity Incentive Plan.

    10-Q

    001-38650

    10.2

    November 7, 2022

    ​

    ​

    ​

    ​

    ​

    ​

    99.4

    Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2018 Equity Incentive Plan.

    S-1

    333-226999

    10.16

    August 24, 2018

    ​

    ​

    ​

    ​

    ​

    ​

    99.5

    Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2018 Equity Incentive Plan.

    S-1

    333-226999

    10.17

    August 24, 2018

    ​

    ​

    ​

    ​

    ​

    ​

    99.6

    Form of Performance Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2018 Equity Incentive Plan.

    10-K

    001-38650

    10.46

    February 29, 2024

    ​

    ​

    ​

    ​

    ​

    ​

    5.1*

    Opinion of Cooley LLP.

    ​

    ​

    23.1*

    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.

    ​

    ​

    23.2*

    Consent of Cooley LLP (included in Exhibit 5.1).

    ​

    ​

    24.1*

    Power of Attorney (included on the signature page of this Form S-8)

    ​

    ​

    107*

    Exhibit Fee Table

    ​

    *

    Filed herewith.

    ​

    2

    ​


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement or amendment thereto to be signed on its behalf by the undersigned, thereunto duly authorized, in Princeton, State of New Jersey, on this 4th day of March 2025.

    Y-MABS THERAPEUTICS, INC.

    By:

    /s/ Michael Rossi

    Name: Michael Rossi

    Title: President and Chief Executive Officer

    ​

    ​

    3

    ​


    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Michael Rossi, Peter Pfreundschuh and John LaRocca, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    Name

       

    Position

       

    Date

    /s/ MICHAEL ROSSI

    Director, President, Chief Executive Officer
    (Principal Executive Officer)

    March 4, 2025

    Michael Rossi

    /s/ PETER PFREUNDSCHUH

    Chief Financial Officer and Treasurer
    (Principal Financial Accounting Officer)

    March 4, 2025

    ​

    Peter Pfreundschuh

    ​

    ​

    ​

    ​

    ​

    /s/ THOMAS GAD

    Director

    March 4, 2025

    Thomas Gad

    /s/ JOHAN WEDELL-WEDELLSBORG

    Director

    March 4, 2025

    Johan Wedell-Wedellsborg

    /s/ LAURA J. HAMILL

    Director

    March 4, 2025

    Laura J. Hamill

    /s/ MARY TAGLIAFERRI

    Director

    March 4, 2025

    Mary Tagliaferri

    /s/ ASHUTOSH TYAGI

    Director

    March 4, 2025

    Ashutosh Tyagi

    /s/ JAMES I. HEALEY

    Director

    March 4, 2025

    James I. Healy

    /s/ DAVID N. GILL

    Director

    March 4, 2025

    David N. Gill

    ​

    4

    ​


    Get the next $YMAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $YMAB

    DatePrice TargetRatingAnalyst
    4/22/2025$3.00Neutral → Underperform
    BofA Securities
    11/18/2024$23.00Outperform
    Oppenheimer
    8/16/2024$20.00Overweight
    Cantor Fitzgerald
    6/28/2024$21.00Buy
    Truist
    5/10/2023$5.00 → $13.00Neutral → Outperform
    Wedbush
    4/3/2023Buy → Neutral
    Guggenheim
    1/27/2023$4.00Equal-Weight → Underweight
    Morgan Stanley
    1/5/2023Outperform → Market Perform
    Cowen
    More analyst ratings

    $YMAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

      NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. "I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head," said Michael Rossi, President and Chief Executive Officer. "We believe Doug's extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our co

      1/10/25 7:35:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

      NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre

      7/1/24 4:05:00 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

      NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. "We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in develop

      6/5/24 7:05:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    Financials

    Live finance-specific insights

    See more

    $YMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $YMAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $YMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

      Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include naxitamab-gqgk (DANYELZA®)Dosed first patient in Phase 1 clinical trial evaluating CD38-SADA pretargeted radioimmunotherapy in patients with Relapsed/Refractory non-Hodgkin Lymphoma (Trial 1201)The Company to host virtual Radiopharmaceutical R&D update discussing Part A clinical data from its Phase I GD2-SADA clinical trial (Trial 1001) and announcing radioimmunotherapy and pipeline strategy on May 28, 2025As of March 31, 2025, cash and cash equiv

      5/13/25 6:35:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

      PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the first quarter 2025 before the market open on Tuesday, May 13, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, May 13, 2025 at 8:00 a.m. ET. A live audio webcast of the call will be available on the Investor Relations section of the Company's website at https://ir.ymabs.com/events-and-presentat

      5/6/25 7:05:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

      Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR

      3/4/25 6:35:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Y-mAbs Therapeutics from Neutral to Underperform and set a new price target of $3.00

      4/22/25 7:23:34 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Y-mAbs Therapeutics with a new price target

      Oppenheimer initiated coverage of Y-mAbs Therapeutics with a rating of Outperform and set a new price target of $23.00

      11/18/24 8:23:54 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Y-mAbs Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Y-mAbs Therapeutics with a rating of Overweight and set a new price target of $20.00

      8/16/24 7:40:36 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wg Biotech Aps bought $44,232 worth of shares (6,455 units at $6.85), increasing direct ownership by 0.14% to 4,559,233 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      12/12/23 8:27:16 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedell-Wedellsborg Johan bought $44,232 worth of shares (6,455 units at $6.85) (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      12/12/23 8:26:25 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wg Biotech Aps bought $40,190 worth of shares (6,183 units at $6.50) and bought $850,222 worth of shares (121,366 units at $7.01), increasing direct ownership by 3% to 4,552,778 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      12/11/23 5:25:50 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

      Company's Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugation of 177Lu-DOTAIncreased tumor retention and total tumor uptake anticipated by using optimized universal RadiohaptenCompany plans to initiate a Trial 1001 Bridge study (Part 2A) with optimized Radiohapten, "Proteus", in 1H 2026 with data readout in 2H 2026; Part B of Trial 1001 anticipated to initiate with Proteus in 1H 2027 with data readout in 2H 2027Expanded Radiopharmaceutical pipeline to focus on target franchise areas in oncology, with specific prog

      5/28/25 6:35:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

      PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of GD2-SADA in recurrent or refractory metastatic solid tumors known to express GD2 in a trial in progress poster at the Advances in Neuroblastoma Research Meeting ("ANR") being held on May 25-28, 2025 in Washington, D.C. The trial in progress poster titled "A phase 1 trial of pretargeted radioimmunotherapy with GD2-SADA: 177Lu-DOTA in patients wit

      5/26/25 10:00:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

      PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will hold a virtual Radiopharmaceutical R&D update at 8:00 a.m. ET on Wednesday, May 28, 2025. During the virtual Radiopharmaceutical R&D update, Y-mAbs will discuss: Part A clinical data from the Company's ongoing Phase 1 GD2-SADA clinical trial (Trial 1001), including pharmacokinetic and dosimetry data; updates around the Company's nonclinical optimization studies

      5/13/25 7:05:00 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Y-mAbs Therapeutics Inc.

      DEFA14A - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

      5/30/25 4:13:09 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Y-mAbs Therapeutics Inc.

      DEF 14A - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

      5/30/25 4:10:32 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Y-mAbs Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

      5/28/25 7:04:45 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $YMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $YMAB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • PRESIDENT & CEO Rossi Michael J sold $20,368 worth of shares (3,917 units at $5.20), decreasing direct ownership by 3% to 137,083 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      3/11/25 8:17:08 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF BUSINESS OFFICER Gad Thomas sold $56,536 worth of shares (10,810 units at $5.23), decreasing direct ownership by 5% to 202,721 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      3/11/25 8:15:41 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Treasurer Pfreundschuh Peter P. was granted 31,800 shares, increasing direct ownership by 69% to 77,800 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      1/22/25 7:05:55 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

      SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

      11/14/24 4:32:10 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

      SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

      11/12/24 6:00:40 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

      SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

      11/4/24 2:16:23 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

      Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

      3/21/24 10:20:07 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care